万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
http://www.karger.com/Journal/Home/224278
3、投稿网址：
https://www.manuscriptmanager.net/RES?product_id=224278
4、官网邮箱：res@karger.com
5、官网电话：+41 61 306 1356
6、期刊刊期：月刊，一年出版12期。
2021年5月25日星期二
投稿须知【官网信息】
Respiration
Author Guidelines
About the Journal
Aims and Scope
Respiration brings together the results of both clinical and experimental investigations on all aspects of the respiratory system in health and disease. Clinical improvements in the diagnosis and treatment of chest and lung diseases are covered, as are the latest findings in physiology, biochemistry, pathology, immunology, and pharmacology. The journal includes classic features such as editorials that accompany original articles in clinical and basic science research, reviews, and letters to the editor. Further sections are: “The Eye Catcher”, “What’s Your Diagnosis?”, “New Insights from Clinical Practice”, and “Guidelines”. Respiration is the official journal of the Swiss Respiratory Society (SGP) and also home to the European Association for Bronchology and Interventional Pulmonology (EABIP), which occupies a dedicated section on interventional pulmonology in the journal. This modern mix of different features and a stringent peer review process by a dedicated editorial board make Respiration a complete guide to progress in thoracic medicine.
Journal Sections
Clinical Investigations
Clinical improvements in the diagnosis and treatment of chest and lung diseases. Including the latest findings in physiology, biochemistry, pathology, immunology and pharmacology.
Interventional Pulmonology
Articles reporting the use of endoscopy and other tools to diagnose and treat conditions in the lungs and chest.
Basic Science Investigations
Experimental investigations on all aspects of the respiratory system in health and disease.
The Eye Catcher
Unlike normal case reports, these articles may not exceed 250 words to allow sufficient space for pictorial material, which is the main object of an Eye Catcher. Maximum 2 references and 2–5 keywords.
What Is Your Diagnosis?
A special kind of case report. Select a catchy title not disclosing the diagnosis. Page 1: Case report and 1–2 illustrations and the question 'What Is Your Diagnosis'. Page 2: The diagnosis followed by a short description of what diagnostic procedures were done to reach the diagnosis and the discussion with references. Maximum 15 references and include 3–5 keywords. No abstract is required.
Guidelines
Consensus Guidelines are welcome from working groups to provide guidance in key and emerging areas in all fields of respiratory medicine. Such guidelines are also subject to a reviewing process.
Clinico-Pathological Conferences
A report of a conference discussion of a case. The case is presented followed by discussion which may include differential diagnosis, clinical diagnosis and pathological diagnosis. The date and location of the discussion should be included as a subtitle. No abstract is required.
Editorial Comments
Submission by invitation only to accompany (same issue) a controversial or interesting manuscript which has been accepted for publication. The author is usually one of the original reviewers.
Thematic Review Series
Series of articles edited by a Guest Editor distributed over one volume of the journal covering a wide range of topics in pulmonary medicine. Articles written by eminent experts in the specialised field. Submission by invitation only.
Novel Insights from Clinical Practice
The Case Report is to include highlighted boxes containing one or two bullet points on 'Established Facts' (what is already known) and 'Novel Insights' (what new information has been gained). These should be selected so as to reinforce the novelty of the clinical observation. Case reports should contain a 200-word abstract and up to 3 figures.
Article Types
Research Article
Research Articles report on primary research. They must describe significant and original observations. Consideration for publication is based on the article’s originality, novelty, and scientific soundness, and the appropriateness of its analysis.
Research Articles are reports of original work. Authors are asked to follow the EQUATOR Network for Research Articles.
Prior approval from an Institutional Review Board (IRB) or an Ethics Review Committee is required for all investigations involving human subjects.
A downloadable template is available below.
Documents
ResearchArticle (DOCX, 28.63 KB)
Research articles should contain a 250-word abstract.
Review Article
Review Articles are considered reviews of research or summary articles. They are state-of-the-art papers covering a current topic by experts in the field. They should give evidence on and provide answers to a well-defined aspect or question in a particular area. Review Articles must include a critical discussion of the reported data and give a clear conclusion with potential impacts on the standard of care.
A downloadable template is available below.
Documents
Review Article (DOCX, 23.75 KB)
Review articles should contain a 250-word unstructured abstract.
Systematic Review
Systematic Reviews are literature reviews focused on a research question that synthesizes all high-quality research evidence relevant to that question. Systematic Reviews should be presented in the Introduction, Methods, Results, Discussion format. The subject must be clearly defined. The objective of a Systematic Review should be to arrive at an evidence-based conclusion. The Methods section should give a clear indication of the literature search strategy, data extraction procedure, grading of evidence, and kind of analysis used. We strongly encourage authors to comply with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
A downloadable template is available below.
Documents
Systematic Review (DOCX, 27.84 KB)
Case Report
Case Reports can present a case study, case report, or other description of a case. Case Reports present significant new insights or cases with an unusual and noteworthy course. Submissions can be based on a case or a number of similar cases. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario or may represent an entirely new clinical condition. The novelty of the case(s) may lie in the phenotype, the presentation, the investigation, and/or the management. We strongly encourage authors to comply with the CARE guidelines.The manuscript must include a statement detailing that written informed consent for publication was obtained and from whom (e.g. “Written informed consent was obtained from the patient for publication of this case report and any accompanying images.”). If the patient has died, consent for publication must be obtained from their next of kin. If the patient described in the case report is a minor or vulnerable, then consent for publication must be obtained from the parent/legal guardian. The completed consent form must be made available to the Editor if requested, and will be treated confidentially.
A downloadable template is available below.
Documents
RES Novel Insights (DOCX, 27.74 KB)
RES What Is Your Diagnosis (DOCX, 26.3 KB)
RES Eye Catcher (DOCX, 26.18 KB)
Authors may submit one of the following Case Reports:
Novel Insights: Please see article template for more information.
Eye Catcher: Please see article template for more information.
What Is Your Diagnosis: Please see article template for more information.
Letter
Letters may explore subjects related to matters discussed in the journal, providing the author’s perspective on a subject. Letters may discuss a recently published article and may lend support or constructively critique the article in line with the author’s experience. The editors reserve the right to share such letters to the authors of the article concerned prior to publication in order to permit response, ideally in the same issue of the journal. Letters should not include original data.
Letters should not exceed 2000 words and have a maximum 15 references & 1 figure/table
A downloadable template is available below.
Documents
Letter (DOCX, 24.24 KB)
Letters should contain no abstract, a 500-word body text, and approx. 5 references.
Meta-Analysis
Works consisting of studies using a quantitative method of combining the results of independent studies (usually drawn from the published literature) and synthesizing summaries and conclusions which may be used to evaluate therapeutic effectiveness, plan new studies, etc. It is often an overview of clinical trials. We strongly encourage authors to comply with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
A downloadable template is available below.
Documents
Meta-Analysis (DOCX, 26.7 KB)
Contact Information
Should you have any problems with your submission, please contact the editorial office:
Lara Grieder
Editorial Office 'Respiration'
S. Karger AG
P.O. Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1356
Fax. +41 61 306 1434
Email: res@karger.com
Editorial and Journal Policies
General Conditions
Only papers written in English are considered. The articles should be comprehensible to a reader who is fluent in English and should be edited prior to submission to ensure that standard English grammar and usage are observed. Use of a professional language editing service prior to submission can help avoid delays with the review process.
All manuscripts are subject to editorial review.
The presentation of manuscripts should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals from the International Committee of Medical Journal Editors (ICMJE).
Karger journals aim to adhere to the COPE Code of Conduct and Best Practice Guidelines.
By submitting an article for publication, the authors agree to the transfer of the copyright to the publisher upon acceptance. Accepted papers become the permanent property of the Journal and may not be reproduced by any means, in whole or in part, without the written consent of the publisher.
The Submission Statement with original (hand-written) signatures is to be provided upon submitting the paper. If it is not possible to collect all signatures on a single document, individual copies should be provided for each author.
Karger recommends the use of original images and materials whenever possible. If a submitted manuscript contains third-party copyright material(s), it is the authors’ sole responsibility to obtain permission from the relevant copyright holder for reusing the material(s), including any associated licensing fee. The copyright and usage information needs to be checked carefully to avoid copyright infringement.
Most publishers offer a quick and easy way to clear permissions for their content via the built-in website application RightsLink or via https://www.copyright.com/get-permissions/. Another widely used licensing tool is PLSClear. Please check the publishers’ websites for the available options and user instructions.
Statements
All submitted manuscripts must contain a Statement of Ethics, a Conflict of Interest Statement, an Author Contributions Statement and a Data Availability Statement after the main body of the text, but before the reference list.
Statement of Ethics
Published research must comply with internationally-accepted standards for research practice and reporting. Manuscripts may be rejected if the editors believe that the research has not been carried out within an appropriate ethical framework, and concerns raised after publication may lead to a correction, retraction, or expression of concern in line with COPE guidelines.
Studies involving human subjects (including research on identifiable human material and data) must have been performed with the approval of an appropriate ethics committee and with appropriate participants’ informed consent in compliance with the Helsinki Declaration.
In the manuscript, authors should specify the name of the ethics committee or other relevant authority who approved the study protocol and provide the reference number where appropriate. If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee who made that decision).
For all research involving human subjects, written informed consent to participate in the study should be obtained from participants (or their parent/legal guardian where appropriate ) and a statement detailing this should appear in the manuscript. For studies involving vulnerable participants or participants at risk of potential coercion, detailed information regarding the steps taken to ensure informed consent must be provided. If consent was not obtained, please specify why and whether this was approved by the ethics committee.
In line with the ICMJE recommendations on the protection of research participants, authors must avoid providing identifying information unless strictly necessary for the submission and participants’ identifiable attributes must be anonymized in the manuscript and its supplementary files, if any. If identifying information is necessary, authors must confirm that the individual has provided written consent for the use of that information in a publication.
Research involving human embryonic stem cells, embryonic germ cells or induced pluripotent stem cells should comply with the ISSCR 'Guidelines for the Conduct of Human Embryonic Stem Cell Research' or an equivalent set of guidelines or applicable regulations.
Case Reports: Manuscripts reporting a case report must include a statement detailing that written informed consent for publication was obtained and from whom (e.g. “Written informed consent was obtained from the patient for publication of this case report and any accompanying images.”). If the patient has died, consent for publication must be obtained from their next of kin. If the patient described in the case report is a minor or vulnerable, then consent for publication must be obtained from the parent/legal guardian. The completed consent form must be made available to the Editor if requested, and will be treated confidentially.
Clinical Trials: In accordance with the ICMJE recommendations, all clinical trials should be registered in a publicly available registry approved by the WHO or ICMJE (see the list here) and the clinical trial number must be clearly stated in the manuscript. Manuscripts reporting clinical trials must adhere to the relevant reporting guidelines for their study design, such as CONSORT for randomized controlled trials, TREND for non-randomized trials, or other relevant reporting guidelines as detailed on the Equator network website.
Karger follows the WHO definition of clinical trials "A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes [...] Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc. This definition includes Phase I to Phase IV trials.”
Studies involving animals: Experimental research on vertebrates or any regulated invertebrates must have been approved by the authors' Institutional Animal Care and Use Committee (IACUC) or equivalent ethics committee and must follow internationally recognized guidelines such as the ARRIVE guidelines. In the manuscript, authors should specify the name of the ethics committee or other relevant authority who approved the study protocol and provide the reference number where appropriate.
If ethics approval was not required, or if the study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee who made that decision). Additional information is expected for studies reporting death of a regulated animal as a likely outcome or planned endpoint. Other types of studies including field studies and non-experimental research on animals must comply with local or international guidelines, and where appropriate must have been approved by an appropriate ethics committee.
Conflict of Interest Statement
Karger endorses the ICMJE recommendations on the ‘Disclosure of Financial and Non-Financial Relationships and Activities, and Conflicts of Interest’. Authors are required to disclose any relationship that could reasonably be perceived by a reader as a potential conflict of interest at the time of submission. All forms of support and financial involvement (e.g. employment, consultancies, honoraria, stock ownership and options, expert testimony, grants or patents received or pending, royalties) which took place in the previous three years should be listed, regardless of their potential relevance to the paper. Also the nonfinancial relationships (personal, political, or professional) that may potentially influence the writing of the manuscript should be declared. The role of the funder in study design; collection, analysis, and interpretation of data; writing of the report; any restrictions regarding the submission of the report for publication should be declared. If the funder had no role in any of the above, this should be clearly stated in the manuscript’s funding section.
Author Contributions Statement
In the Author Contributions section, a short statement detailing the contributions of each person named as an author should be included. Contributors to the paper who do not fulfill the ICMJE Criteria for Authorship should be credited in the Acknowledgement section. If an author is removed from or added to the listed authors after submission, an explanation and a signed statement of agreement confirming the requested change are required from all the initially listed authors and from the author to be removed or added.
Data Availability Statement
The journal’s data sharing policy strongly encourages authors to make all datasets on which the conclusions of the paper rely available to editors, reviewers and readers without unnecessary restriction wherever possible. Authors are required to provide a Data Availability Statement in their article that details whether data are available and where they can be found. In cases where research data are not publicly available on legal or ethical grounds, this should be clearly stated in the Data Availability Statement along with any conditions for accessing the data. The decision to publish will not be affected by whether or not authors share their research data.
Examples of Data Availability statements:
·The data that support the findings of this study are openly available in [repository name e.g “figshare”] at http://doi.org/[doi], reference number [reference number]
· Publicly available datasets were used in this study. These can be found in [repository name e.g “figshare”] at http://doi.org/[doi], reference number [reference number]
·All data generated or analyzed during this study are included in this article [and/or] its supplementary material files. Further enquiries can be directed to the corresponding author.
·The data that support the findings of this study are not publicly available due to [REASON WHY DATA ARE NOT PUBLIC e.g. their containing information that could compromise the privacy of research participants] but are available from [e.g. the corresponding author [author initials] OR Data sharing committee [PROVIDE CONTACT DETAILS including email address] upon reasonable request]
·The data in this study was obtained from [third party source] where [RESTRICTIONS/LICENCE] may apply. Such dataset may be requested from [source contact information].
Please note if authors are submitting to a journal with a double blind peer review policy, the data availability statement should be anonymized where appropriate.
……
更多详情：
https://www.karger.com/Journal/Guidelines/224278
